Therapies

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

22 days ago   |   By Xconomy

A Blueprint Medicines cancer drug candidate currently under FDA review will have the marketing muscle of Roche behind it if it wins regulatory approval. The two companies are partnering on the drug, pralsetinib, a targeted cancer therapy developed for lung and thyroid cancers characterized by abnormalities in a gene called RET. According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. The Swiss pharmaceutical giant agreed to pay Cambridge, MA-based Blueprint $675 million up front...
Read more ...

 


Search by Tags

   Therapies      Pharmaceutical      Gene      Pharmaceuticals      Drugs      Medicine      Drug      Cancer      Genes      Boston      Boston blog main      Boston top stories      National blog main      National top stories      San Francisco blog main      San Francisco top stories      Avapritinib      Biotech      Blueprint Medicines      Clinical trials      Cstone Pharmaceuticals      Deals      Eli Lilly      European Medicines Agency      FDA      Fisogatinib      Flatiron Health      Genentech      Hepatocellular carcinoma      Investing      Jeff Albers      Life Sciences      Medullary thyroid cancer      Non-Small Cell Lung Cancer      Pralsetinib      Roche      Selpercatinib      Thermo Fisher Scientific      Thyroid Cancer  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It's a particularly pronounced problem for therapies employing... Read more ...

AbbVie Walks From Voyager R&D Pact Spanning Alzheimer's, Parkinson's

AbbVie Walks From Voyager R&D Pact Spanning Alzheimer's, Parkinson's

A partnership between Voyager Therapeutics and AbbVie developing gene therapies for Alzheimer's and Parkinson's has ended without a drug for either disease reaching human... Read more ...

Interpreting the Human Genome's Instruction Manual

Interpreting the Human Genome's Instruction Manual

An artistic representation of gene regulating elements, which allow cells with the same genetic code to differentiate into many different tissues and play many varied roles in... Read more ...

IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

About six months after the FDA approved the first treatment for peanut allergy, a new biotech, IgGenix, has raised $10 million to discover antibodies that could address that... Read more ...

As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up

As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up

Telemedicine giant Teladoc Health is buying health technology company Livongo Health in an $18.5 billion cash and stock deal that comes as the COVID-19 pandemic drives patients... Read more ...

Kristin Persson Named Director of Berkeley Lab's Molecular Foundry

Kristin Persson Named Director of Berkeley Lab's Molecular Foundry

Kristin Persson Kristin Persson, a senior faculty scientist in the Energy Storage & Distributed Resources Division within the Energy Technologies Area at Lawrence Berkeley... Read more ...

Geothermal Brines Could Propel California's Green Economy

Geothermal Brines Could Propel California's Green Economy

Thermal mud pots at Controlled Thermal Resources' project site at the Salton Sea. Deep beneath the surface of the Salton Sea, a shallow lake in California's Imperial County... Read more ...

Still Stuck on Adhesion Issues, FDA Rejects DBV's Peanut Allergy Patch

Still Stuck on Adhesion Issues, FDA Rejects DBV's Peanut Allergy Patch

A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs... Read more ...

CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage

CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage

CymaBay Therapeutics' investigational drug seladelpar succeeded in a late-stage trial in patients with primary biliary cholangitis , producing results that suggest it could... Read more ...

PDR: a new genome assembly evaluation metric based on genetics concerns

AbstractMotivationExisting genome assembly evaluation metrics provide only limited insight on specific aspects of genome assembly quality, and sometimes even disagree with each... Read more ...